IN2015MN00436A - - Google Patents

Info

Publication number
IN2015MN00436A
IN2015MN00436A IN436MUN2015A IN2015MN00436A IN 2015MN00436 A IN2015MN00436 A IN 2015MN00436A IN 436MUN2015 A IN436MUN2015 A IN 436MUN2015A IN 2015MN00436 A IN2015MN00436 A IN 2015MN00436A
Authority
IN
India
Prior art keywords
sequence
protein
contiguous nucleotides
bont
nucleic acid
Prior art date
Application number
Other languages
English (en)
Inventor
Aimee Cossins
Matthew Beard
Original Assignee
Syntaxin Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Ipsen Biopharm Ltd filed Critical Syntaxin Ltd
Publication of IN2015MN00436A publication Critical patent/IN2015MN00436A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN436MUN2015 2012-10-31 2013-10-31 IN2015MN00436A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
IN2015MN00436A true IN2015MN00436A (cs) 2015-09-04

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
IN436MUN2015 IN2015MN00436A (cs) 2012-10-31 2013-10-31

Country Status (26)

Country Link
US (1) US10030238B2 (cs)
EP (3) EP3326644B1 (cs)
JP (2) JP2019068823A (cs)
KR (2) KR102188539B1 (cs)
CN (2) CN110499321A (cs)
AR (2) AR093309A1 (cs)
AU (3) AU2013340610B2 (cs)
BR (1) BR112015005384A2 (cs)
CA (1) CA2885519A1 (cs)
DK (2) DK3326644T3 (cs)
EA (1) EA201590794A8 (cs)
ES (2) ES2788199T3 (cs)
GB (1) GB201219602D0 (cs)
HU (2) HUE048802T2 (cs)
IL (1) IL237623B (cs)
IN (1) IN2015MN00436A (cs)
MX (2) MX367080B (cs)
NO (1) NO2914282T3 (cs)
NZ (1) NZ705575A (cs)
PL (2) PL3326644T3 (cs)
PT (2) PT2914282T (cs)
SG (2) SG11201502372SA (cs)
TW (3) TW202012622A (cs)
UA (1) UA118837C2 (cs)
WO (1) WO2014068317A1 (cs)
ZA (1) ZA201501449B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
HK1248737A1 (zh) * 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒桿菌神經毒素
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
JP7579046B2 (ja) 2016-03-02 2024-11-07 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー ボツリヌス毒素を含む組成物
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
EP3694489A4 (en) 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
CN119020332A (zh) * 2018-01-29 2024-11-26 益普生生物制药有限公司 切割非神经元snare的肉毒杆菌神经毒素
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
DE69937890D1 (de) 1998-07-10 2008-02-14 U S Army Medical Res Inst Of I Impfstoffe gegen neurotoxine von clostridium botulinum
EP2264052A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
CN1946738A (zh) * 2005-03-03 2007-04-11 阿勒根公司 用于纯化肉毒毒素的不含动物产物的系统和方法
CA2610103A1 (en) * 2005-09-19 2007-03-19 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
CA2657521A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP2178905B1 (en) 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
KR20110106346A (ko) * 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CA2758274C (en) * 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
AU2010353292A1 (en) * 2009-12-16 2012-07-12 Allergan, Inc. Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
US20150247139A1 (en) 2015-09-03
KR20150094590A (ko) 2015-08-19
BR112015005384A2 (pt) 2017-08-08
EP2914282A1 (en) 2015-09-09
SG10201701140WA (en) 2017-04-27
ES2662402T3 (es) 2018-04-06
IL237623A0 (en) 2015-04-30
KR20200110470A (ko) 2020-09-23
TW201435084A (zh) 2014-09-16
MX2019009222A (es) 2019-11-21
PL3326644T3 (pl) 2020-08-24
EP3673914B1 (en) 2021-10-27
HUE036764T2 (hu) 2018-07-30
TW202012622A (zh) 2020-04-01
AU2013340610A1 (en) 2015-03-19
JP2020078321A (ja) 2020-05-28
HUE048802T2 (hu) 2020-08-28
MX367080B (es) 2019-08-05
ZA201501449B (en) 2016-08-31
MX2015005156A (es) 2015-09-23
CA2885519A1 (en) 2014-05-08
PL2914282T3 (pl) 2018-07-31
US10030238B2 (en) 2018-07-24
KR102264478B1 (ko) 2021-06-15
EP3673914A1 (en) 2020-07-01
DK3326644T3 (da) 2020-05-11
CN104755098A (zh) 2015-07-01
AR093309A1 (es) 2015-05-27
PT2914282T (pt) 2018-03-13
AU2018203556A1 (en) 2018-06-07
EA201590794A8 (ru) 2016-01-29
DK2914282T3 (en) 2018-02-26
EP3326644A1 (en) 2018-05-30
IL237623B (en) 2019-05-30
AU2020244481A1 (en) 2020-10-29
EP3326644B1 (en) 2020-03-04
NZ705575A (en) 2019-08-30
KR102188539B1 (ko) 2020-12-09
TWI673361B (zh) 2019-10-01
ES2788199T3 (es) 2020-10-20
AU2018203556B2 (en) 2020-08-20
NO2914282T3 (cs) 2018-05-19
CN110499321A (zh) 2019-11-26
GB201219602D0 (en) 2012-12-12
UA118837C2 (uk) 2019-03-25
SG11201502372SA (en) 2015-05-28
TW201825680A (zh) 2018-07-16
JP2019068823A (ja) 2019-05-09
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
AR117738A2 (es) 2021-08-25
AU2013340610B2 (en) 2018-02-22
PT3326644T (pt) 2020-05-29
WO2014068317A1 (en) 2014-05-08
HK1208359A1 (en) 2016-03-04
TWI626307B (zh) 2018-06-11

Similar Documents

Publication Publication Date Title
IN2015MN00436A (cs)
PH12014501726A1 (en) Glyphosate resistant plants and associated methods
MX337985B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
MX379251B (es) Producción mejorada de derivados de ácidos grasos.
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX2015005797A (es) Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica.
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
NZ729980A (en) Genes involved in noscapine production
BR112017020690A2 (pt) produção livre de células de ácido ribonucleico
IN2015DN03206A (cs)
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
MX2014003403A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
MX2015007775A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
IN2014DN05672A (cs)
MX2014013255A (es) Endoglucanasas con propiedades mejoradas.
AU2011350442B2 (en) Modified tamavidin